PathAI and Cleveland Clinic Announce Collaboration to Build Digital Pathology Infrastructure and Evolve Use of AI-Powered Pathology Algorithms in Research and Clinical Care


Excerpt from the Press Release: BOSTON & CLEVELAND–(BUSINESS WIRE)–PathAI, a global leader in artificial intelligence (AI)-powered technology for pathology, and Cleveland Clinic today announced a five-year strategic collaboration that will focus on leveraging PathAI’s quantitative pathology algorithms both to conduct new translational research and for use as clinical diagnostics in multiple disease areas. This collaborative effort combines…

Read More

Naveris’ Head and Neck Cancer Recurrence Detection Study Selected for Presentation at ASTRO 2022 Plenary Session


Excerpt from the Press Release: NATICK, Mass.–(BUSINESS WIRE)–Naveris, Inc., a leader in molecular diagnostics for viral cancers, today announced the presentation of significant new data at the plenary session of the ASTRO 2022 Multidisciplinary Head and Neck Cancers Symposium supporting the clinical value of its flagship diagnostic test, NavDx®. In a real-world analysis of 1,076…

Read More

Clear Creek Bio Advances Its Highly Potent SARS-CoV-2 PLpro Inhibitors in Discovery of an Oral Direct-Acting Antiviral to Treat COVID-19


Clear Creek Bio signed a CRADA with the NIH to support its SARS-CoV-2 PLpro inhibitor discovery This CRADA was initiated as part of the Antiviral Program for Pandemics (APP) Via APP, Clear Creek will be able to use the NIH’s current and expanded contract resources and NCATS laboratories to prioritize the advancement of antiviral candidates…

Read More

DiaCarta Enters a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Develop Cancer Tests based on its Novel XNA Technology


Excerpt from the Press Release: PLEASANTON, Calif., Jan. 5, 2022 /PRNewswire/ — DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy today announced that the company, under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health, will collaborate on…

Read More

Allarity Therapeutics and Oncoheroes Biosciences Sign Agreements to Advance Pediatric Cancer Development of Dovitinib and Stenoparib


Oncoheroes will fund and advance the clinical development of both dovitinib and stenoparib in pediatric cancers, utilizing Allarity’s DRP® companion diagnostics Allarity has submitted a new drug application (NDA) for the U.S. approval of dovitinib in renal cell carcinoma (RCC) together with the Dovitinib-DRP® companion diagnostic Excerpt from the Press Release: Cambridge, MA U.S.A. (January 3, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage biopharmaceutical company developing novel oncology therapeutics…

Read More

Sorrento Announces COVISTIX COVID-19 Virus Rapid Antigen Detection Test Detects the Omicron Variant


COVISTIX maintains its ability to detect the Omicron Variant, in addition to detecting SARS-CoV-2 and all of its major variants of concern (VoCs); COVISTIX has the potential to be a “Best-in-Class” rapid COVID-19 virus antigen detection test: Comparative studies with all available EUA-approved COVID-19 virus rapid antigen detection tests demonstrated that COVISTIX significantly outperforms in…

Read More

Quidel’s Antigen Tests Detect the Omicron Variant


Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, issued the following statement from Douglas Bryant, Quidel’s President and CEO, regarding Quidel’s ongoing efforts to evaluate COVID-19 mutations and confirm that its antigen tests continue to detect COVID-19…

Read More

Vincerx Pharma Announces First Patient Dosed in Phase 1 Dose-Escalation Study of VIP152 in Relapsed or Refractory Chronic Lymphocytic Leukemia or Richter Syndrome


Excerpt from the Press Release: PALO ALTO, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that the first patient has been dosed in the Company’s Phase 1 dose-escalation study of VIP152 in…

Read More

BioNTech says it will know in 2 weeks whether the COVID-19 vaccine it developed with Pfizer works against the new variant rapidly spreading in southern Africa


BioNTech is testing its COVID vaccine against a rapidly spreading variant, the Financial Times said. The B.1.1.529 variant has been detected in South Africa, Botswana, Hong Kong, and Israel. Excerpt from the Press Release: BioNTech said it’s testing the COVID-19 vaccine it developed with Pfizer against the new variant that appears to have emerged in southern Africa, and that it would know in two weeks…

Read More

Blood Cancer UK partners with RareCan to improve delivery of clinical trials


Charity Blood Cancer UK has teamed up with oncology company RareCan to support the organisation’s delivery of clinical trials focussed on the prevention, diagnosis, or treatment of rare cancers. Excerpt from the Press Release: Blood cancer The partnership will see Blood Cancer UK join the charity network GIST Cancer UK as RareCan’s partner. The aim…

Read More